The word TRETHERA in bold, modern font with horizontal orange bars incorporated into the letters E and H on a light background.The word TRETHERA in bold, modern font with horizontal orange bars incorporated into the letters E and H on a light background.White text TRETHERA on a light gray background, with orange horizontal bars inside the letters E and H. The design is modern and minimalistic.

A portfolio inside a single product.

TRE-515 is a first-in-class oral therapy with clinical data in oncology and preclinical evidence across a range of autoimmune indications. It’s one mechanism, generating many shots on goal, advanced with a capital-efficient, largely non-dilutive strategy.

A portfolio inside a single product.

TRE-515 is a first-in-class oral therapy with clinical data in oncology and preclinical evidence across a range of autoimmune indications. It’s one mechanism, generating many shots on goal, advanced with a capital-efficient, largely non-dilutive strategy.

The opportunity

Why Trethera.

A single focused target, a broad portfolio built on it, and a track record of efficiently converting capital into clinical progress.

Pipeline in a product

One drug, TRE-515, supports 7+ indications across oncology, autoimmune disease, and ALS. Each program is a distinct shot on goal built on the same mechanism, so progress in one can de-risk the others.

Capital efficient

More than $17M in non-dilutive NIH grant funding as of July 2026 has advanced the science to date, extending the reach of every invested dollar without diluting shareholders.

Clinical Progress

A completed dose-escalation portion of the ongoing clinical trial showed a favorable safety profile and confirmed target engagement, with disease control in 14/30 evaluable patients (47%), including prolonged stable disease in some patients.

Protected and designated

FDA Fast Track and Orphan Drug designations support the lead programs, with U.S. structural and methods of use patent protection potentially extending through 2046.

Value-adding events

Key Milestones to Date

>35

Patients treated (dose escalation complete)

>$17M

Non-dilutive NIH grant funding

>7

Indications supported by preclinical data
2045
Patent protection through
FDA
Fast Track + Orphan Drug designations
Understanding biotech value

Where value is created.

In drug development, value builds in steps. Each time investment is converted into intellectual property, through new data, a patent, a manufacturing advance, a grant, or an FDA designation, risk comes down, and value can step up. Trethera’s lead program has crossed its first clinical milestone, with a broad portfolio behind it.

Value can step up at each de-risking event
Preclinical data
Clinical data
Patents & IP
Manufacturing advances
Non-dilutive grants
FDA designations
Illustrative and educational only. Not a forecast, valuation, or projection of Trethera’s value. Each program carries its own risk and timeline.
For qualified investors

Qualified Small Business Stock (QSBS).

As an early-stage company, Trethera may qualify under the federal Qualified Small Business Stock provisions, which can offer meaningful tax advantages to eligible investors.

For qualified investors

Qualified Small Business Stock (QSBS).

As an early-stage company, Trethera may qualify under the federal Qualified Small Business Stock provisions, which can offer meaningful tax advantages to eligible investors.